Court Rejects Preemption, Asks FDA To Defend Pregnancy Label Warning For OTC Acetaminophen
Executive Summary
Ruling on pre-trial motion in complaint against a Kenvue business in District Court for Southern New York is first in litigation alleging damages from using OTC monograph drug to find against federal preemption of state consumer protection laws and similar regulations.
You may also be interested in...
Court Wants Defense Of Acetaminophen Pregnancy Warning, US FDA Provides Research Review
Review makes clear FDA’s thinking on safety acetaminophen use during pregnancy, but likely won’t sway federal judge from her conclusion that a warning about risks of in utero exposure could be added to drug containing the ingredient and available under an OTC monograph without violating FDA regulations.
Federal Preemption Strikes California Prop 65 Complaint Against Generic OTC Ranitidine Firms
Whether California court finds Zantac, when marketed containing ranitidine, should have had a Prop 65 label warning could be influenced by dismissal in federal court of class action complaints due to faulty research behind claims that ranitidine causes a carcinogenic substance to form post-production.
Supreme Court Strengthens Generic Liability Shield; FDA Reg Change Could Create Opening
The high court rules 5-4 that generic drug makers cannot be sued for alleged design defects based on the adequacy of a drug’s label warnings; FDA continues to discuss revising its regulations to allow generic companies to change their labeling.